FDA – Page 3 – Policy & Medicine

Allergan Botox Settlement and Corporate Integrity Agreement

Milwaukee Journal Sentinel: The Case of BMP-2 Ignoring Any Benefit from Innovation

FDA and Disease Awareness Programs

FDA Opioid REMS: ACPE Outlines Pharmacists Role in Education

FDA: Warning Letters May Double in 2010

FDA Opioid REMS Advisory Panel Focus on CME for Improving Practice

FDA Pain REMS Advisory Committee to Include Presentations on Continuing Education in the Health Professions as a Tool for Implementation

FDA Avandia Hearing Update – Committee Votes to Keep Avandia on the Market but with Restrictions

FDA Direct to Consumer Proposed Rule: Advertising Coalition’s Response

FDA Turns to CME for Risk Evaluation and Mitigation Strategy (REMS) Pain Education